aluates Reports

$ 0.0

Automative

Global Non-Hodgkin Lymphoma Treatment Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-28Y5679

Global Non Hodgkin Lymphoma Treatment Market Size Status and Forecast 2021 2027

BUY CHAPTERS

Global Non-Hodgkin Lymphoma Treatment Market Research Report 2025

Code: QYRE-Auto-28Y5679

Report

July 2025

Pages:85

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Takeda Pharmaceutical Company Limited

Astrazeneca plc

Bayer

Novartis

Gilead Sciences

Spectrum Pharmaceuticals

Teva Pharmaceutical Industries Ltd

Bristol Myers Squibb Company

Janssen Pharmaceuticals

Roche

CELGENE CORPORATION (Bristol Myers Squibb Company)

Merck& Co. Inc

Kyowa Kirin Co., Ltd.

AbbVie

Sanofi

Non-Hodgkin Lymphoma Treatment Market Size

The global market for Non-Hodgkin Lymphoma Treatment was valued at US$ 8990 million in the year 2024 and is projected to reach a revised size of US$ 14530 million by 2031, growing at a CAGR of 7.2% during the forecast period.

Non-Hodgkin Lymphoma Treatment Market

Non-Hodgkin’s lymphomas are one of the most commonly occurring cases of lymphomas and hence is also one of the most commonly occurring cancers. If not treated effectively, it is potentially lethal and leads to a shorter life span of the individuals diagnosed.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Non-Hodgkin Lymphoma Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Hodgkin Lymphoma Treatment.

The Non-Hodgkin Lymphoma Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Hodgkin Lymphoma Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-Hodgkin Lymphoma Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-Hodgkin Lymphoma Treatment Market Report

Report Metric	Details
Report Name	Non-Hodgkin Lymphoma Treatment Market
Accounted market size in year	US$ 8990 million
Forecasted market size in 2031	US$ 14530 million
CAGR	7.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Immunotherapy Targeted Therapy Chemotherapy Others
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer, Novartis AG, Gilead Sciences, Spectrum Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Janssen Pharmaceuticals, Roche, CELGENE CORPORATION (Bristol Myers Squibb Company), Merck & Co., Inc., Kyowa Kirin Co., Ltd., AbbVie, Sanofi
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Hodgkin Lymphoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Non-Hodgkin Lymphoma Treatment Market growing?

Ans: The Non-Hodgkin Lymphoma Treatment Market witnessing a CAGR of 7.2% during the forecast period 2025-2031.

What is the Non-Hodgkin Lymphoma Treatment Market size in 2031?

Ans: The Non-Hodgkin Lymphoma Treatment Market size in 2031 will be US$ 14530 million.

Who are the main players in the Non-Hodgkin Lymphoma Treatment Market report?

Ans: The main players in the Non-Hodgkin Lymphoma Treatment Market are Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer, Novartis AG, Gilead Sciences, Spectrum Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Janssen Pharmaceuticals, Roche, CELGENE CORPORATION (Bristol Myers Squibb Company), Merck & Co., Inc., Kyowa Kirin Co., Ltd., AbbVie, Sanofi

What are the Application segmentation covered in the Non-Hodgkin Lymphoma Treatment Market report?

Ans: The Applications covered in the Non-Hodgkin Lymphoma Treatment Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

What are the Type segmentation covered in the Non-Hodgkin Lymphoma Treatment Market report?

Ans: The Types covered in the Non-Hodgkin Lymphoma Treatment Market report are Immunotherapy, Targeted Therapy, Chemotherapy, Others

Recommended Reports

Lymphoma & Leukemia

Wider Cancer Therapeutics

Hematological Disorders

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Immunotherapy

1.2.3 Targeted Therapy

1.2.4 Chemotherapy

1.2.5 Others

1.3 Market by Application

1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2020-2031)

2.2 Global Non-Hodgkin Lymphoma Treatment Growth Trends by Region

2.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Size by Region (2020-2025)

2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2026-2031)

2.3 Non-Hodgkin Lymphoma Treatment Market Dynamics

2.3.1 Non-Hodgkin Lymphoma Treatment Industry Trends

2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers

2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges

2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue

3.1.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue (2020-2025)

3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Non-Hodgkin Lymphoma Treatment Revenue

3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio

3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2024

3.5 Global Key Players of Non-Hodgkin Lymphoma Treatment Head office and Area Served

3.6 Global Key Players of Non-Hodgkin Lymphoma Treatment, Product and Application

3.7 Global Key Players of Non-Hodgkin Lymphoma Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Hodgkin Lymphoma Treatment Breakdown Data by Type

4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2020-2025)

4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2026-2031)

5 Non-Hodgkin Lymphoma Treatment Breakdown Data by Application

5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2020-2025)

5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2020-2031)

6.2 North America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025)

6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2020-2031)

7.2 Europe Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025)

7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size (2020-2031)

8.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size (2020-2031)

9.2 Latin America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025)

9.4 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size (2020-2031)

10.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Takeda Pharmaceutical Company Limited

11.1.1 Takeda Pharmaceutical Company Limited Company Details

11.1.2 Takeda Pharmaceutical Company Limited Business Overview

11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction

11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.1.5 Takeda Pharmaceutical Company Limited Recent Development

11.2 AstraZeneca

11.2.1 AstraZeneca Company Details

11.2.2 AstraZeneca Business Overview

11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction

11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.2.5 AstraZeneca Recent Development

11.3 Bayer

11.3.1 Bayer Company Details

11.3.2 Bayer Business Overview

11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction

11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.3.5 Bayer Recent Development

11.4 Novartis AG

11.4.1 Novartis AG Company Details

11.4.2 Novartis AG Business Overview

11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction

11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.4.5 Novartis AG Recent Development

11.5 Gilead Sciences

11.5.1 Gilead Sciences Company Details

11.5.2 Gilead Sciences Business Overview

11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction

11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.5.5 Gilead Sciences Recent Development

11.6 Spectrum Pharmaceuticals

11.6.1 Spectrum Pharmaceuticals Company Details

11.6.2 Spectrum Pharmaceuticals Business Overview

11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction

11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.6.5 Spectrum Pharmaceuticals Recent Development

11.7 Teva Pharmaceutical Industries Ltd.

11.7.1 Teva Pharmaceutical Industries Ltd. Company Details

11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction

11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development

11.8 Bristol Myers Squibb Company

11.8.1 Bristol Myers Squibb Company Company Details

11.8.2 Bristol Myers Squibb Company Business Overview

11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction

11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.8.5 Bristol Myers Squibb Company Recent Development

11.9 Janssen Pharmaceuticals

11.9.1 Janssen Pharmaceuticals Company Details

11.9.2 Janssen Pharmaceuticals Business Overview

11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction

11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.9.5 Janssen Pharmaceuticals Recent Development

11.10 Roche

11.10.1 Roche Company Details

11.10.2 Roche Business Overview

11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction

11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.10.5 Roche Recent Development

11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)

11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details

11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview

11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction

11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development

11.12 Merck & Co., Inc.

11.12.1 Merck & Co., Inc. Company Details

11.12.2 Merck & Co., Inc. Business Overview

11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction

11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.12.5 Merck & Co., Inc. Recent Development

11.13 Kyowa Kirin Co., Ltd.

11.13.1 Kyowa Kirin Co., Ltd. Company Details

11.13.2 Kyowa Kirin Co., Ltd. Business Overview

11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction

11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.13.5 Kyowa Kirin Co., Ltd. Recent Development

11.14 AbbVie

11.14.1 AbbVie Company Details

11.14.2 AbbVie Business Overview

11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction

11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.14.5 AbbVie Recent Development

11.15 Sanofi

11.15.1 Sanofi Company Details

11.15.2 Sanofi Business Overview

11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction

11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

11.15.5 Sanofi Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Takeda Pharmaceutical Company Limited

Astrazeneca plc

Bayer

Novartis

Gilead Sciences

Spectrum Pharmaceuticals

Teva Pharmaceutical Industries Ltd

Bristol Myers Squibb Company

Janssen Pharmaceuticals

Roche

CELGENE CORPORATION (Bristol Myers Squibb Company)

Merck& Co. Inc

Kyowa Kirin Co., Ltd.

AbbVie

Sanofi

List of Tables

Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Immunotherapy

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Chemotherapy

Table 5. Key Players of Others

Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2020-2025)

Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2026-2031)

Table 12. Non-Hodgkin Lymphoma Treatment Market Trends

Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers

Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges

Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints

Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players (2020-2025)

Table 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2024)

Table 19. Ranking of Global Top Non-Hodgkin Lymphoma Treatment Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Non-Hodgkin Lymphoma Treatment, Headquarters and Area Served

Table 22. Global Key Players of Non-Hodgkin Lymphoma Treatment, Product and Application

Table 23. Global Key Players of Non-Hodgkin Lymphoma Treatment, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2020-2025)

Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2026-2031)

Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2020-2025)

Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2026-2031)

Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 48. Takeda Pharmaceutical Company Limited Company Details

Table 49. Takeda Pharmaceutical Company Limited Business Overview

Table 50. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product

Table 51. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 52. Takeda Pharmaceutical Company Limited Recent Development

Table 53. AstraZeneca Company Details

Table 54. AstraZeneca Business Overview

Table 55. AstraZeneca Non-Hodgkin Lymphoma Treatment Product

Table 56. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 57. AstraZeneca Recent Development

Table 58. Bayer Company Details

Table 59. Bayer Business Overview

Table 60. Bayer Non-Hodgkin Lymphoma Treatment Product

Table 61. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 62. Bayer Recent Development

Table 63. Novartis AG Company Details

Table 64. Novartis AG Business Overview

Table 65. Novartis AG Non-Hodgkin Lymphoma Treatment Product

Table 66. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 67. Novartis AG Recent Development

Table 68. Gilead Sciences Company Details

Table 69. Gilead Sciences Business Overview

Table 70. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product

Table 71. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 72. Gilead Sciences Recent Development

Table 73. Spectrum Pharmaceuticals Company Details

Table 74. Spectrum Pharmaceuticals Business Overview

Table 75. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product

Table 76. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 77. Spectrum Pharmaceuticals Recent Development

Table 78. Teva Pharmaceutical Industries Ltd. Company Details

Table 79. Teva Pharmaceutical Industries Ltd. Business Overview

Table 80. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Product

Table 81. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 82. Teva Pharmaceutical Industries Ltd. Recent Development

Table 83. Bristol Myers Squibb Company Company Details

Table 84. Bristol Myers Squibb Company Business Overview

Table 85. Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Product

Table 86. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 87. Bristol Myers Squibb Company Recent Development

Table 88. Janssen Pharmaceuticals Company Details

Table 89. Janssen Pharmaceuticals Business Overview

Table 90. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product

Table 91. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 92. Janssen Pharmaceuticals Recent Development

Table 93. Roche Company Details

Table 94. Roche Business Overview

Table 95. Roche Non-Hodgkin Lymphoma Treatment Product

Table 96. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 97. Roche Recent Development

Table 98. CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details

Table 99. CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview

Table 100. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Product

Table 101. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 102. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development

Table 103. Merck & Co., Inc. Company Details

Table 104. Merck & Co., Inc. Business Overview

Table 105. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product

Table 106. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 107. Merck & Co., Inc. Recent Development

Table 108. Kyowa Kirin Co., Ltd. Company Details

Table 109. Kyowa Kirin Co., Ltd. Business Overview

Table 110. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product

Table 111. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 112. Kyowa Kirin Co., Ltd. Recent Development

Table 113. AbbVie Company Details

Table 114. AbbVie Business Overview

Table 115. AbbVie Non-Hodgkin Lymphoma Treatment Product

Table 116. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 117. AbbVie Recent Development

Table 118. Sanofi Company Details

Table 119. Sanofi Business Overview

Table 120. Sanofi Non-Hodgkin Lymphoma Treatment Product

Table 121. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2020-2025) & (US$ Million)

Table 122. Sanofi Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Non-Hodgkin Lymphoma Treatment Picture

Figure 2. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2024 VS 2031

Figure 4. Immunotherapy Features

Figure 5. Targeted Therapy Features

Figure 6. Chemotherapy Features

Figure 7. Others Features

Figure 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2024 VS 2031

Figure 10. Hospital Pharmacies Case Studies

Figure 11. Retail Pharmacies Case Studies

Figure 12. Online Pharmacies Case Studies

Figure 13. Others Case Studies

Figure 14. Non-Hodgkin Lymphoma Treatment Report Years Considered

Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Region: 2024 VS 2031

Figure 18. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2024

Figure 19. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2024

Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2020-2031)

Figure 23. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2020-2031)

Figure 27. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Region (2020-2031)

Figure 35. China Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2020-2031)

Figure 43. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Country (2020-2031)

Figure 47. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 51. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 52. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 53. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 54. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 55. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 56. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 57. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 58. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 59. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 60. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 61. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 62. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 63. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 64. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

B Cell Non Hodgkin s Lymphoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non Hodgkin s Lymphoma and Chronic Lymphoma Treatment Market Research Report 2024

Global Non Hematological Cancer Treatment Market Research Report 2024

Global Non Hematological Cancers Market Research Report 2024

Global Follicular Lymphoma Treatment Market Research Report 2025

Non Hodgkin Lymphoma Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non Melanoma Skin Cancer Treatment Market Research Report 2024

Global Follicular Lymphoma Drugs Market Research Report 2025

B Cell Non Hodgkin s Lymphoma NHL Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Canine Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lymphoma Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non Melanoma Skin Cancer Market Research Report 2024

Global Non small Cell Lung Cancer Drugs Market Insights Forecast to 2030

Hematologic Malignancies Detection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anaplastic Large Cell Lymphoma Treatment Market Insights Forecast to 2030

Lymphoblastic Lymphoma Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lymphoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Hodgkin s Lymphoma Drugs Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions